Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.31,9164,DB00784,Mefenamic acid
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.28,9165,DB00784,Mefenamic acid
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.2,9166,DB00784,Mefenamic acid
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],10.5,9167,DB00784,Mefenamic acid
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],3.3,9168,DB00784,Mefenamic acid
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],7.8,9169,DB00784,Mefenamic acid
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9170,DB00784,Mefenamic acid
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9171,DB00784,Mefenamic acid
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9172,DB00784,Mefenamic acid
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9173,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9174,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,19,9175,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,63,9176,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,109,9177,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9178,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,13,9179,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,49,9180,DB00784,Mefenamic acid
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,122,9181,DB00784,Mefenamic acid
,24102566,Papp,"In the presence of MEF, Papp of B, W and OA were increased from 1.69 ± 0.89 × 10⁻⁶, 1.57 ± 0.10 × 10⁻⁶ and 3.09 ± 0.70 × 10⁻⁶ cm/sec to 5.24 ± 0.27 × 10⁻⁶, 6.08 ± 0.19 × 10⁻⁶ and 4.13 ± 0.38 × 10⁻⁶, whereas their percentage of metabolism was decreased from 72.75 ± 2.44%, 73.27 ± 3.25% and 89.84 ± 2.99% to 21.11 ± 0.69%, 17.90 ± 5.55% and 45.44 ± 3.38%.",Influence of mefenamic acid on the intestinal absorption and metabolism of three bioactive flavones in Radix Scutellariae and potential pharmacological impact. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102566/),[10⁻⁶·cm] / [s],1.69,12359,DB00784,Mefenamic acid
,24102566,Papp,"In the presence of MEF, Papp of B, W and OA were increased from 1.69 ± 0.89 × 10⁻⁶, 1.57 ± 0.10 × 10⁻⁶ and 3.09 ± 0.70 × 10⁻⁶ cm/sec to 5.24 ± 0.27 × 10⁻⁶, 6.08 ± 0.19 × 10⁻⁶ and 4.13 ± 0.38 × 10⁻⁶, whereas their percentage of metabolism was decreased from 72.75 ± 2.44%, 73.27 ± 3.25% and 89.84 ± 2.99% to 21.11 ± 0.69%, 17.90 ± 5.55% and 45.44 ± 3.38%.",Influence of mefenamic acid on the intestinal absorption and metabolism of three bioactive flavones in Radix Scutellariae and potential pharmacological impact. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102566/),[10⁻⁶·cm] / [s],1.57,12360,DB00784,Mefenamic acid
,24102566,Papp,"In the presence of MEF, Papp of B, W and OA were increased from 1.69 ± 0.89 × 10⁻⁶, 1.57 ± 0.10 × 10⁻⁶ and 3.09 ± 0.70 × 10⁻⁶ cm/sec to 5.24 ± 0.27 × 10⁻⁶, 6.08 ± 0.19 × 10⁻⁶ and 4.13 ± 0.38 × 10⁻⁶, whereas their percentage of metabolism was decreased from 72.75 ± 2.44%, 73.27 ± 3.25% and 89.84 ± 2.99% to 21.11 ± 0.69%, 17.90 ± 5.55% and 45.44 ± 3.38%.",Influence of mefenamic acid on the intestinal absorption and metabolism of three bioactive flavones in Radix Scutellariae and potential pharmacological impact. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102566/),[10⁻⁶·cm] / [s],3.09,12361,DB00784,Mefenamic acid
,24102566,Papp,"In the presence of MEF, Papp of B, W and OA were increased from 1.69 ± 0.89 × 10⁻⁶, 1.57 ± 0.10 × 10⁻⁶ and 3.09 ± 0.70 × 10⁻⁶ cm/sec to 5.24 ± 0.27 × 10⁻⁶, 6.08 ± 0.19 × 10⁻⁶ and 4.13 ± 0.38 × 10⁻⁶, whereas their percentage of metabolism was decreased from 72.75 ± 2.44%, 73.27 ± 3.25% and 89.84 ± 2.99% to 21.11 ± 0.69%, 17.90 ± 5.55% and 45.44 ± 3.38%.",Influence of mefenamic acid on the intestinal absorption and metabolism of three bioactive flavones in Radix Scutellariae and potential pharmacological impact. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102566/),10⁻⁶,5.24,12362,DB00784,Mefenamic acid
,24102566,Papp,"In the presence of MEF, Papp of B, W and OA were increased from 1.69 ± 0.89 × 10⁻⁶, 1.57 ± 0.10 × 10⁻⁶ and 3.09 ± 0.70 × 10⁻⁶ cm/sec to 5.24 ± 0.27 × 10⁻⁶, 6.08 ± 0.19 × 10⁻⁶ and 4.13 ± 0.38 × 10⁻⁶, whereas their percentage of metabolism was decreased from 72.75 ± 2.44%, 73.27 ± 3.25% and 89.84 ± 2.99% to 21.11 ± 0.69%, 17.90 ± 5.55% and 45.44 ± 3.38%.",Influence of mefenamic acid on the intestinal absorption and metabolism of three bioactive flavones in Radix Scutellariae and potential pharmacological impact. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102566/),,6.08,12363,DB00784,Mefenamic acid
,24102566,Papp,"In the presence of MEF, Papp of B, W and OA were increased from 1.69 ± 0.89 × 10⁻⁶, 1.57 ± 0.10 × 10⁻⁶ and 3.09 ± 0.70 × 10⁻⁶ cm/sec to 5.24 ± 0.27 × 10⁻⁶, 6.08 ± 0.19 × 10⁻⁶ and 4.13 ± 0.38 × 10⁻⁶, whereas their percentage of metabolism was decreased from 72.75 ± 2.44%, 73.27 ± 3.25% and 89.84 ± 2.99% to 21.11 ± 0.69%, 17.90 ± 5.55% and 45.44 ± 3.38%.",Influence of mefenamic acid on the intestinal absorption and metabolism of three bioactive flavones in Radix Scutellariae and potential pharmacological impact. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102566/),,4.13,12364,DB00784,Mefenamic acid
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 µl⋅min-1⋅mg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],2.42,34460,DB00784,Mefenamic acid
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 µl⋅min-1⋅mg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],2.82,34461,DB00784,Mefenamic acid
,29138287,CLint,"Of other enzymes displaying activity (UGT1A3, UGT1A9, UGT1A10-H, and UGT2B4), UGT2B4 (CLint,u 0.51 µl⋅min-1⋅mg-1) was estimated to contribute significantly to the hepatic clearance.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],0.51,34462,DB00784,Mefenamic acid
,7395889,extraction efficiency,The extraction efficiency of the hollow-fiber kidneys averaged 6.4%.,Hemodialysis of mefenamic acid in uremic patients. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395889/),%,6.4,37608,DB00784,Mefenamic acid
,7395889,drug recovery,The mean drug recovery was 1.03 mg or 0.2% of the administered dose.,Hemodialysis of mefenamic acid in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395889/),mg,1.03,37609,DB00784,Mefenamic acid
,7395889,drug recovery,The mean drug recovery was 1.03 mg or 0.2% of the administered dose.,Hemodialysis of mefenamic acid in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395889/),%,0.2,37610,DB00784,Mefenamic acid
,7395889,plasma protein binding,The extensive plasma protein binding (range: 85-97%) accounted for the poor recovery.,Hemodialysis of mefenamic acid in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395889/),%,85-97,37611,DB00784,Mefenamic acid
,33314761,ratio of area under the plasma concentration-time curves (AUCR ),"Using the verified compound files, PBPK modeling predicted an ertugliflozin ratio of area under the plasma concentration-time curves (AUCR ) of 1.51 when co-administered with MFA.",Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314761/),,1.51,63507,DB00784,Mefenamic acid
,22116543,T(max),The test product exhibited faster absorption (T(max) of 1.87 ± 0.482 vs. 2.14 ± 0.20 h; C(max) of 5.91 ± 0.604 vs. 3.58 ± 0.671 μg/ml) when compared to the reference.,In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116543/),h,1.87,73381,DB00784,Mefenamic acid
,22116543,T(max),The test product exhibited faster absorption (T(max) of 1.87 ± 0.482 vs. 2.14 ± 0.20 h; C(max) of 5.91 ± 0.604 vs. 3.58 ± 0.671 μg/ml) when compared to the reference.,In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116543/),h,2.14,73382,DB00784,Mefenamic acid
,22116543,C(max),The test product exhibited faster absorption (T(max) of 1.87 ± 0.482 vs. 2.14 ± 0.20 h; C(max) of 5.91 ± 0.604 vs. 3.58 ± 0.671 μg/ml) when compared to the reference.,In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116543/),[μg] / [ml],5.91,73383,DB00784,Mefenamic acid
,22116543,C(max),The test product exhibited faster absorption (T(max) of 1.87 ± 0.482 vs. 2.14 ± 0.20 h; C(max) of 5.91 ± 0.604 vs. 3.58 ± 0.671 μg/ml) when compared to the reference.,In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116543/),[μg] / [ml],3.58,73384,DB00784,Mefenamic acid
,22116543,relative bioavailability,The relative bioavailability of the test compared to the reference capsule was 172%.,In vitro/in vivo correlation of fast release mephenamic acid microspheres in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116543/),%,172,73385,DB00784,Mefenamic acid
,22275128,flow-rate,"Chromatographic separation was achieved on a Thermo Hypurity C(18) , 50 × 4.6 mm, 5 µm column with a mobile phase consisting of 2 m m ammonium acetate buffer and methanol (pH 4.5 adjusted with glacial acetic acid; 15:85, v/v) at a flow-rate of 0.75 mL/min and the total run time was 1.75 min.",A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),[ml] / [min],0.75,75285,DB00784,Mefenamic acid
,22275128,total run time,"Chromatographic separation was achieved on a Thermo Hypurity C(18) , 50 × 4.6 mm, 5 µm column with a mobile phase consisting of 2 m m ammonium acetate buffer and methanol (pH 4.5 adjusted with glacial acetic acid; 15:85, v/v) at a flow-rate of 0.75 mL/min and the total run time was 1.75 min.",A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),min,1.75,75286,DB00784,Mefenamic acid
,22275128,dwell time,"Both the drug and IS were detected in negative-ion mode using multiple reaction monitoring m/z 240.0 → 196.3 and m/z 294.0 → 250.2, respectively, with a dwell time of 200 ms for each of the transitions.",A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),ms,200,75287,DB00784,Mefenamic acid
,22275128,recovery,The observed mean recovery was 73% for the drug.,A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22275128/),%,73,75288,DB00784,Mefenamic acid
,7161340,detection limit,The assay is quantitative down to 0.25 microgram ml-1 from a 200-microliters aliquot of plasma with a detection limit of 0.1 microgram ml-1 and a recovery of approximately 90%.,High-performance liquid chromatographic assay of indomethacin and its application in pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161340/),[μg] / [ml],0.1,82634,DB00784,Mefenamic acid
,7161340,recovery,The assay is quantitative down to 0.25 microgram ml-1 from a 200-microliters aliquot of plasma with a detection limit of 0.1 microgram ml-1 and a recovery of approximately 90%.,High-performance liquid chromatographic assay of indomethacin and its application in pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161340/),%,90,82635,DB00784,Mefenamic acid
>,18508416,Extraction recoveries,Extraction recoveries of drug from plasma were >48.14%.,A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18508416/),%,48.14,90195,DB00784,Mefenamic acid
,18620910,limit of detection,The limit of detection was 50 pg/mL (signal/noise >3).,A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18620910/),[pg] / [ml],50,120546,DB00784,Mefenamic acid
>,18620910,signal/noise,The limit of detection was 50 pg/mL (signal/noise >3).,A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18620910/),,3,120547,DB00784,Mefenamic acid
,26109199,metabolic to,"The systemic exposure of these identified metabolites was high, with metabolic to parent AUC0 → 24 h ratios reaching 23-52% (OH-MEFs) and 8-29% (OH-MEFGs).",Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109199/),%,23-52,126219,DB00784,Mefenamic acid
,26109199,AUC0 → 24 h ratios,"The systemic exposure of these identified metabolites was high, with metabolic to parent AUC0 → 24 h ratios reaching 23-52% (OH-MEFs) and 8-29% (OH-MEFGs).",Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109199/),%,23-52,126220,DB00784,Mefenamic acid
,26109199,AUC0 → 24 h ratios,"The systemic exposure of these identified metabolites was high, with metabolic to parent AUC0 → 24 h ratios reaching 23-52% (OH-MEFs) and 8-29% (OH-MEFGs).",Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109199/),%,8-29,126221,DB00784,Mefenamic acid
,26109199,elimination half-lives,"These metabolites also had a long systemic exposure time in both single and 5 day multiple oral MEF-treated rats, with elimination half-lives between 9 h and > 24 h.",Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109199/),h,9,126222,DB00784,Mefenamic acid
>,26109199,elimination half-lives,"These metabolites also had a long systemic exposure time in both single and 5 day multiple oral MEF-treated rats, with elimination half-lives between 9 h and > 24 h.",Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109199/),h,24,126223,DB00784,Mefenamic acid
,25980420,AUC0→24[PGE2],"The PGE2 level in LPS-stimulated RAW264.7 cells treated with plasma collected from control group over the 24h sampling (AUC0→24[PGE2]) was 191981±8789pg/mlhr, which was significantly reduced to 174,780±6531 and 46,225±1915pg/mlhr by plasma collected from rats administered with SR extract and MEF, respectively.","Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25980420/),[pg] / [mlhr],191981,176253,DB00784,Mefenamic acid
,25980420,AUC0→24[PGE2],"The PGE2 level in LPS-stimulated RAW264.7 cells treated with plasma collected from control group over the 24h sampling (AUC0→24[PGE2]) was 191981±8789pg/mlhr, which was significantly reduced to 174,780±6531 and 46,225±1915pg/mlhr by plasma collected from rats administered with SR extract and MEF, respectively.","Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25980420/),[pg] / [mlhr],"174,780",176254,DB00784,Mefenamic acid
,25980420,AUC0→24[PGE2],"The PGE2 level in LPS-stimulated RAW264.7 cells treated with plasma collected from control group over the 24h sampling (AUC0→24[PGE2]) was 191981±8789pg/mlhr, which was significantly reduced to 174,780±6531 and 46,225±1915pg/mlhr by plasma collected from rats administered with SR extract and MEF, respectively.","Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25980420/),[pg] / [mlhr],"46,225",176255,DB00784,Mefenamic acid
,25980420,AUC0→24,"Co-administration of SR extract and MEF further potentiated the PGE2 inhibition, with an AUC0→24[PGE2] of 37013±2354pg/mlhr (p<0.05, compared to SR or MEF group).","Herb-drug interactions between Scutellariae Radix and mefenamic acid: Simultaneous investigation of pharmacokinetics, anti-inflammatory effect and gastric damage in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25980420/),[pg] / [mlhr],37013,176256,DB00784,Mefenamic acid
,7942001,peak plasma concentration (Cmax),"There were marked inter-individual differences in some of the pharmacokinetic parameters after the first dose; peak plasma concentration (Cmax) varied from 1.2 to 6.1 micrograms/mL with a mean of 3.8 micrograms/mL, time to reach Cmax (tmax) varied from 2 to 18 h with a mean of 7.7 h and plasma half-life (t1/2) varied from 3.8 to 43.6 h with a mean of 18.7 h.",Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7942001/),[μg] / [ml],3.8,187998,DB00784,Mefenamic acid
,7942001,time to reach Cmax (tmax),"There were marked inter-individual differences in some of the pharmacokinetic parameters after the first dose; peak plasma concentration (Cmax) varied from 1.2 to 6.1 micrograms/mL with a mean of 3.8 micrograms/mL, time to reach Cmax (tmax) varied from 2 to 18 h with a mean of 7.7 h and plasma half-life (t1/2) varied from 3.8 to 43.6 h with a mean of 18.7 h.",Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7942001/),h,7.7,187999,DB00784,Mefenamic acid
,7942001,plasma half-life (t1/2),"There were marked inter-individual differences in some of the pharmacokinetic parameters after the first dose; peak plasma concentration (Cmax) varied from 1.2 to 6.1 micrograms/mL with a mean of 3.8 micrograms/mL, time to reach Cmax (tmax) varied from 2 to 18 h with a mean of 7.7 h and plasma half-life (t1/2) varied from 3.8 to 43.6 h with a mean of 18.7 h.",Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7942001/),h,18.7,188000,DB00784,Mefenamic acid
,19353730,flow-rate,"The method involves simple, one-step liquid-liquid extraction procedure coupled with an Acquity UPLC(TM) BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with isocratic elution at a flow-rate of 0.2 mL/min and mefenamic acid was used as the internal standard.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),[ml] / [min],0.2,233667,DB00784,Mefenamic acid
,19353730,recovery,"The recovery was 66.7% and 52.6% for fenofibric acid, and mefenamic acid, respectively.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),%,66.7,233668,DB00784,Mefenamic acid
,19353730,recovery,"The recovery was 66.7% and 52.6% for fenofibric acid, and mefenamic acid, respectively.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),%,52.6,233669,DB00784,Mefenamic acid
,19353730,Total run time,"Total run time was 1.8 min only for each sample, which makes it possible to analyze more than 350 samples per day.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),min,1.8,233670,DB00784,Mefenamic acid
,9223760,t1/2s,"On the other hand the acetyloxyethyl mefenamate shows t1/2s of 1.4 h, 1.41 h and 3.61 h in human plasma, solutions of pH 7.4 and pH 1.0 respectively; However, its hydrolysis to mefenamic acid in plasma was not quantitative.",Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9223760/),h,1.4,240470,DB00784,Mefenamic acid
,9223760,t1/2s,"On the other hand the acetyloxyethyl mefenamate shows t1/2s of 1.4 h, 1.41 h and 3.61 h in human plasma, solutions of pH 7.4 and pH 1.0 respectively; However, its hydrolysis to mefenamic acid in plasma was not quantitative.",Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9223760/),h,1.41,240471,DB00784,Mefenamic acid
,9223760,t1/2s,"On the other hand the acetyloxyethyl mefenamate shows t1/2s of 1.4 h, 1.41 h and 3.61 h in human plasma, solutions of pH 7.4 and pH 1.0 respectively; However, its hydrolysis to mefenamic acid in plasma was not quantitative.",Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9223760/),h,3.61,240472,DB00784,Mefenamic acid
,9223760,AUC0-inf,The calculated AUC0-inf for the acetyloxyethyl and control were 45 and 85 micrograms.h/ml respectively.,Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9223760/),[h·μg] / [ml],45,240473,DB00784,Mefenamic acid
,9223760,AUC0-inf,The calculated AUC0-inf for the acetyloxyethyl and control were 45 and 85 micrograms.h/ml respectively.,Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9223760/),[h·μg] / [ml],85,240474,DB00784,Mefenamic acid
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00784,Mefenamic acid
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00784,Mefenamic acid
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00784,Mefenamic acid
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00784,Mefenamic acid
